Sarah Cannon Research UK and BioMarin collaborate on EMBRACA clinical study
BioMarin announced a collaboration to enroll patients in an ongoing Phase 3 clinical trial of its PARP inhibitor, BMN 673, for treatment of hereditary breast cancer with a BRCA mutation. This trial has been named EMBRACA. Sarah Cannon Research UK enrolled the first patient outside of the U.S. July 23, 2014